{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-028420","form_type":"8-K/A","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.751724+00:00","generated_at":"2026-05-26T17:07:11.806972+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cabaletta reports deepened rese-cel responses: 3 SLE patients in DORIS remission, LN complete renal response","bullets":["3 of 4 non-renal SLE patients achieved DORIS remission; first LN patient achieved complete renal response; all off immunosuppressants and steroids.","First adult dermatomyositis patient maintained major TIS improvement at 3 months, off immunosuppressants and tapering steroids.","Safety: 90% had no CRS or Grade 1 CRS; 90% had no ICANS across first 10 patients dosed with rese-cel.","Deep B cell depletion within first month; repopulation with naïve phenotype starting ~2 months post-infusion; tissue depletion confirmed by lymph node biopsy.","50 clinical sites recruiting in US/Europe; 26 patients enrolled across RESET program as of Feb 13, 2025; average 1 patient/week since November."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-028420","json":"https://secwatch.observer/filing/0001193125-25-028420.json","markdown":"https://secwatch.observer/filing/0001193125-25-028420.md","text":"https://secwatch.observer/filing/0001193125-25-028420.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000119312525028420/0001193125-25-028420-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000119312525028420/d925657d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T17:07:11.806972+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}